Treatment of protein degradation disorders

1. A method of treating a subject suffering from or susceptible to cancer comprising administering to a subject in need thereof a therapeutically effective amount of a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor selectively inhibits HDAC6.

2. The method of claim 1 , wherein the cancer is multiple myeloma, leukemia, lymphoma, breast cancer, lung cancer or liver cancer.

3. The method of claim 1 , wherein the cancer is multiple myeloma.

4. The method of claim 1 , wherein the proteasome inhibitor is bortezomib.

5. A method of treating a cell exhibiting symptoms of cancer comprising administering a therapeutically effective amount of a proteasome inhibitor and an aggresome inhibitor to the cell, wherein the aggresome inhibitor selectively inhibits HDAC6.

6. The method of claim 5 , wherein the cell is one or more of a cell from a subject or a cultured cell.

7. The method of claim 6 , wherein the cell from a subject is one or more of bone marrow stromal cell (BMSC), a peripheral blood mononuclear cell (PBMC), lymphocytes, hair follicles, blood cells, other epithelial cells, bone marrow plasma cells, primary cancer cells, patient derived tumor cells, normal or cancerous hematopoietic stem cells, neural stem cells, solid tumor cells, or astrocytes.

8. The method of claim 6 , wherein the cultured cell is one or more of MM.1S, U266, RPMI8226, DOX40, MM.1R, INA-6, LR5, primary and established cancer cell lines, and primary and established normal cell lines.

9. The method of claim 1 , wherein the proteasome inhibitor is selected from the group consisting of bortezomib, MG132, sapojargon, and NPI-0052.

10. The method of claim 1 , wherein the aggresome inhibitor is of the formula:

wherein

R 1 is cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR A ; —C(═O)R A ; —CO 2 R A ; —SR A ; —SOR A ; —SO 2 R A ; —N(R A ) 2 ; —NHC(O)R A ; or —C(R A ) 3 ; wherein each occurrence of R B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 2 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstitued, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR B ; —C(═O)R B ; —CO 2 R B ; —CN; —SCN; —SR B ; —SOR B ; —SO 2 R B ; —NO 2 ; —N(R B ) 2 ; —NHC(O)R B ; or —C(R B ) 3 ; wherein each occurrence of R B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; and

R 3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstitued, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR C ; —C(═O)R C ; —CO 2 R C ; —CN; —SCN; —SR C ; —SOR C ; —SO 2 R C ; —NO 2 ; —N(R C ) 2 ; —NHC(O)R C ; or —C(R C ) 3 ; wherein each occurrence of R C is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; and pharmaceutically acceptable salts and derivatives thereof.

11. The method of claim 1 , wherein the aggresome inhibitor is of the formula:

and pharmaceutically acceptable derivatives thereof;

wherein R 1 is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

n is 1-5;

R 2 is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

X is —O—, —C(R 2A ) 2 —, —S—, or —NR 2A —, wherein R 2A is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

or wherein two or more occurrences of R 2 and R 2A , taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety;

R 3 is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; and

Y is hydrogen or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety.

12. A method of treating a subject suffering from or susceptible to cancer comprising administering to a subject in need thereof a therapeutically effective amount of a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor is one of the formulae:

13. The method of claim 1 , wherein the aggresome inhibitor is a compound of formula:

14. The method of claim 12 , wherein the aggresome inhibitor is of the formula:

15. The method of claim 1 , wherein the aggresome inhibitor is a compound of formula:

wherein,

each X is independently O, S, CH 2 , or NR 3 ;

Y is O, S, CH 2 , or NR 4 ;

Ar 1 and Ar 2 are each independently an aryl group;

R 1 is a lower alkyl group or an aryl group;

R 2 is hydrogen, a lower alkyl group or an aryl group; and

R 3 is hydrogen, a lower alkyl group, an aryl group, an alkylcarbonyl, an alkoxycarbonyl group, or an aminocarbonyl group.

16. The method of claim 15 ,

wherein,

X is for both occurrences O;

Y is S;

Ar 1 is phenyl or substituted phenyl;

Ar 2 is heteroaryl;

R 1 is phenyl or substituted phenyl;

R 2 is hydrogen.

17. The method of claim 1 , wherein the aggresome inhibitor inhibits the C-terminal aceylation activity of HDAC6, thereby inhibiting aggresome mediated protein degradation.

18. The method of claim 1 , wherein the proteasome inhibitor is one or more of bortezomib, MG132, sapojargon, or NPI-0052.

19. The method of claim 1 , wherein the aggresome inhibitor is dyenin.

20. The method of claim 1 , further comprising obtaining a biological sample from a subject.

21. The method of claim 1 , further comprising administering a therapeutically effective amount of one or more additional protein degradation inhibitors to the subject or cell.

22. The method of claim 21 , wherein at least one of the additional protein degradation inhibitors is an aggresome inhibitor.

23. The method of claim 21 , wherein at least one of the additional protein degradation inhibitors is a proteasome inhibitor.

24. The method of claim 1 further comprising monitoring the treatment or progress of the cell or subject.

25. The method of claim 1 further comprising co-administering one or more of a chemotherapeutic agent, radiation agent, hormonal agent, biological agent or an anti-inflammatory agent to the subject.

26. The method of claim 25 , wherein the chemotherapeutic agent is tamoxifen, trastuzamab, raloxifene, doxorubicin, fluorouracil/5-fu, pamidronate disodium, anastrozole, exemestane, cyclophos phamide, epirubicin, letrozole, toremifene, fulvestrant, fluoxymester one, trastuzumab, methotrexate, megastrol acetate, docetaxel, paclitaxel, testolactone, aziridine, vinblastine, capecitabine, goselerin acetate, zoledronic acid, taxol, or vincristine.

27. A method of inhibiting protein degradation in a cell comprising contacting the cell with a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor selectively inhibits HDAC6.

28. The method of claim 27 , wherein the aggresome inhibitor is tubacin or a compound of claim 10 .

29. The method of claim 1 further comprising determining a phenotype of the cell after an initial period of treatment with the protein degradation inhibitor.

30. The method of claim 29 , wherein the phenotype is a biological or clinical sequelae in response to a particular treatment or compound, including anemia, thrombocytopenia, neutropenia, osteolytic lesions, bone pain, immunodeficiency, renal insufficiency, hypercalcemia, aneuploidy of mature plasma cells, percentage of malignant cells, acetylation state of tubulin, apoptosis of mature plasma cells, level of aggresomes, level of aggresomes in mature plasma cells, HDAC6 ubiquitination, HDAC6 ubiquitination in mature plasma cells, HDAC6 association with dynein in mature plasma cells, cellular levels of ubiquitinated proteins in mature plasma cells, level of caspase-8 in mature plasma cells, level of PARP in mature plasma cells, thymidine uptake in mature plasma cells, dilated ER cisternae, aggregation of mature plasma cells, deposits of immunoglobulins in mature plasma cells, acetylation state of non-histone proteins, global ubiquitination state of the cellular proteins, state of cell cycle regulation, necrosis, markers of apoptosis, apoptosis state, Russell body formation, cystic fibrosis transmembrane protein receptor state, and modulation of cellular protein deposits, or global acetylation state of cellular and extracellular proteins.

31. The method of claim 15 ,

wherein,

X is for both occurrences O;

Y is S;

Ar 1 is phenyl or substituted phenyl;

Ar 2 is optionally substituted oxazolyl;

R 1 is 4-aminosubstituted phenyl; and

R 2 is hydrogen.

32. The method of claim 1 , wherein the subject is a human.